Neoadjuvant chemotherapy (NAC) is now recommended to treat muscle-invasive bladder cancer (MIBC) but is not always executed in real life. This study aims to evaluate the proportion of patients with MIBC who receive an optimal NAC, and to present the predictive factors of its achievement.
{{header-clinical-trials-navigation}} A Randomized, Controlled, Open-Label Study of the Efficacy, Durability, and Safety of UGN-102 With or Without TURBT in Patients With Low Grade Intermediate Risk Non-Muscle-Invasive Bladder Cancer (LG IR NMIBC) Condition: Bladder Cancer, Urothelial Carcinoma, Urothelial Carcinoma Bladder Study Type: Interventional Clinical Trials Identifier NCT 8-digits: NCT04688931 Sponsor: UroGen Pharma Ltd. Phase: Phase 3 […]
Diane Newman: Welcome. I’m Diane Newman. I’m an Adult Nurse Practitioner at Penn Urology, University of Pennsylvania, and I specialize in pelvic floor dysfunction. I’m here tonight with a colleague of mine, Dr. Scott MacDiarmid. He’s from Alliance Neurology Specialists in Greensboro, North Carolina, and I asked him to share some really new information about […]
Despite the initial success of androgen deprivation therapy (ADT) in treating hormone-sensitive prostate adenocarcinoma, patients inevitably develop tumors that become unresponsive to ADT known as castration-resistant prostate cancer (CRPC). CRPC represents a heterogeneous disease including multiple molecular phenotypes and clinical presentations including small cell neuroendocrine prostate cancer (NEPC) which encompasses approximately 20% of CRPC. NEPC […]
Most studies indicate no benefit of adjuvant therapy with VEGFR tyrosine kinase inhibitors in advanced renal cell carcinoma (RCC). PROTECT (NCT01235962) was a randomized, double-blind, placebo-controlled phase 3 study to evaluate adjuvant pazopanib in patients with locally advanced RCC at high risk of relapse after nephrectomy (pazopanib, n = 769; placebo, n = 769).
Cabozantinib is approved for metastatic renal cell carcinoma (mRCC) based on the METEOR and CABOSUN trials. However, real-world effectiveness and dosing patterns of cabozantinib are not well characterized.
The current pathological tumour-node-metastasis (pTNM) classification for upper tract urothelial carcinoma (UTUC) does not include any risk stratification of pT3 renal pelvicalyceal tumours. To assess the prognostic impact of pT3 subclassification in a multicentre cohort of patients with UTUC of the renal pelvicalyceal system undergoing radical nephroureterectomy (RNU).
To comprehensively investigate the role of otoferlin as a prognostic and diagnostic biomarker in clear cell renal cell carcinoma. Three independent cohorts were used to study otoferlin in clear cell renal cell carcinoma: The Cancer Genome Atlas cohort (messenger ribonucleic acid expression; clear cell renal cell carcinoma n = 514, normal renal tissue n = 81); study validation cohort […]
Cabazitaxel (25 mg/m2 every 3 weeks) is the standard second-line chemotherapy for patients with metastatic castration-resistant prostate cancer previously treated with docetaxel. It is associated with a risk of neutropenic complications, which may be a barrier to its use in daily clinical practice, particularly in frail elderly patients.
The homologous recombination deficiency (HRD) score integrates three DNA-based measures of genomic instability, and has been understudied in prostate cancer. Given the recent FDA approval of two PARP inhibitors for prostate cancer, HRD score analysis could help to refine treatment selection.
